MX2015001008A - Formulacion de misoprostol. - Google Patents

Formulacion de misoprostol.

Info

Publication number
MX2015001008A
MX2015001008A MX2015001008A MX2015001008A MX2015001008A MX 2015001008 A MX2015001008 A MX 2015001008A MX 2015001008 A MX2015001008 A MX 2015001008A MX 2015001008 A MX2015001008 A MX 2015001008A MX 2015001008 A MX2015001008 A MX 2015001008A
Authority
MX
Mexico
Prior art keywords
likelihood
female
misoprostol
insert
infection
Prior art date
Application number
MX2015001008A
Other languages
English (en)
Inventor
Barbara L Powers
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12178114.0A external-priority patent/EP2689802A1/en
Priority claimed from EP13150704.8A external-priority patent/EP2754443A1/en
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2015001008A publication Critical patent/MX2015001008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para reducir la probabilidad de infección que requiere el uso de antibióticos durante o después de la inducción del trabajo de parto en una mujer, comprende administrar por la ruta intravaginal a la mujer un inserto que comprende un producto de reacción de poliuretano reticulado de un polietilenglicol, un triol y un diisocianato, el inserto contiene 200 µg de misoprostol; la probabilidad de infección es reducida en comparación con la administración del inserto que contiene 10 mg de dinoprostona.
MX2015001008A 2012-07-26 2013-07-25 Formulacion de misoprostol. MX2015001008A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12178114.0A EP2689802A1 (en) 2012-07-26 2012-07-26 Misoprostol formulation
EP13150704.8A EP2754443A1 (en) 2013-01-09 2013-01-09 Misoprostol for the induction of labour
PCT/EP2013/065759 WO2014016390A1 (en) 2012-07-26 2013-07-25 Misoprostol formulation

Publications (1)

Publication Number Publication Date
MX2015001008A true MX2015001008A (es) 2015-04-09

Family

ID=48875056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001008A MX2015001008A (es) 2012-07-26 2013-07-25 Formulacion de misoprostol.

Country Status (12)

Country Link
US (1) US20150238414A1 (es)
EP (1) EP2877182A1 (es)
JP (2) JP2015522645A (es)
KR (1) KR20150034796A (es)
CN (1) CN104487077A (es)
AU (2) AU2013294956B2 (es)
CA (1) CA2880260A1 (es)
EA (2) EA030124B1 (es)
HK (1) HK1211204A1 (es)
IL (1) IL236574A0 (es)
MX (1) MX2015001008A (es)
WO (1) WO2014016390A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683487A (en) * 1947-04-30 1954-07-13 Danly Mach Specialties Inc Forming machine and stacker therefor
ATE14979T1 (de) 1979-03-21 1985-09-15 Nat Res Dev Zusammensetzung mit geregelter wirkstofffreigabe und verfahren zu ihrer herstellung.
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
JP4165733B2 (ja) 1998-12-30 2008-10-15 クエスト・インターナショナル・サービシーズ・ビー・ブイ Ｃ１２乃至ｃ２２脂肪酸に基づくモノ及びジグリセリドのジアセチル酒石酸エステル類
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006089561A1 (en) * 2005-02-23 2006-08-31 Abbas Abdelsalam Ghazi Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix.
US20130197081A1 (en) * 2010-06-11 2013-08-01 Ferring B.V. Intravaginal administration of misoprostol
US9162722B1 (en) * 2014-05-21 2015-10-20 Crops Co., Ltd. Vibration alarm device for a bicycle

Also Published As

Publication number Publication date
AU2013294956A1 (en) 2015-01-22
US20150238414A1 (en) 2015-08-27
EP2877182A1 (en) 2015-06-03
EA201492239A1 (ru) 2015-06-30
CA2880260A1 (en) 2014-01-30
AU2013294956B2 (en) 2018-03-08
WO2014016390A1 (en) 2014-01-30
CN104487077A (zh) 2015-04-01
KR20150034796A (ko) 2015-04-03
EA030124B1 (ru) 2018-06-29
IL236574A0 (en) 2015-02-26
JP2015522645A (ja) 2015-08-06
JP2018184412A (ja) 2018-11-22
HK1211204A1 (en) 2016-05-20
EA201890414A1 (ru) 2018-06-29
AU2018201139A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL223481B (en) Insert comprising misoprostol and a cross-linked reaction product of a diisocyanate, a triol and a polyethylene glycol for intravaginal administration in a nulliparous female
MX357598B (es) Dispositivos intravaginales para administración de fármaco.
PH12016501083A1 (en) Drug delivery system
MY183859A (en) Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
WO2014053966A3 (en) Customizable cushion utilizing fitted plug inserts
MX2015001008A (es) Formulacion de misoprostol.
PH12014501352A1 (en) Non-enteric pharmaceutical composition comprising crofelemer
GB201100804D0 (en) Drug combination
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol
UA70547U (ru) Способ прегравидарной подготовки женщин с синдромом потери плода в анамнезе на фоне хронического эндометрита
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
MD520Y (en) Method for postoperative treatment of patients with nephrolithiasis
UA65795U (ru) Способ профилактики преэклампсии при многоплодии
UA88598U (uk) Спосіб лікування кишкових інфекцій
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
UA60203U (ru) Способ профилактики заболеваний желудочно-кишечного тракта у новорожденных телят
UA92718U (ru) Способ профилактики послеоперационных раневых осложнений аллогерниопластики передней брюшной стенки
TN2016000171A1 (en) Drug delivery system.
UA80468U (ru) Способ лечения молярно-резцовой гипоминерализации эмали у детей
UA58749U (ru) Способ лечения стеатоза печени у больных туберкулезом
UA64822U (ru) Способ медицинской реабилитации больных неалкогольным стеатогепатитом
UA72300U (ru) Способ лечения пролиферативной витреоретинопатии при травмах глазного яблока в раннем пост-травматическом периоде
UA69975U (ru) Способ коррекции показателей клеточного звена иммунитета у больных неалкогольным стеатогепатитом